期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 14, 期 9, 页码 2254-2262出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1469591
关键词
Hepatitis E; HEV; Vaccine; Advance
资金
- National Key Research and Development Program of China [2017YFD0500104, 2016YFD0500904]
- National Natural Science Foundation of China [31572531]
Hepatitis E virus (HEV) infection is an emerging zoonotic disease posing a severe threat to public health in the world, especially to pregnant women. Currently, no specific treatments are available for HEV infection. Therefore, it is crucial to develop vaccine to prevent this infection. Although several potential candidate vaccines against HEV have been studied for their immunogenicity and efficacy, only Hecolin (R) which is developed by Xiamen Innovax Biotech Co., Ltd. and approved by China Food and Drug Administration (CFDA) in 2012, is the licensed HEV vaccine in the world so far. Extensive studies on safety, immunogenicity and efficacy in phase III clinical trials have shown that Hecolin (R) is a promising vaccine for HEV prevention and control. In this article, the advances on HEV vaccine development and research are briefly reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据